Federal anti-money laundering investigators have cracked down on an illicit pharmaceutical network accused of repackaging cheap bulk formulations as high-end brand antibiotics and distributing them to hospitals.
Searches swept across five premises in Bengaluru under Section 17 of the Prevention of Money Laundering Act. During the operation, the Directorate of Enforcement froze a bank account holding approximately ₹9 lakh belonging to an accused named Veeresh Kumar, while seizing digital drives and distribution ledgers. The financial probe stems directly from an August 18 joint raid by police personnel and the Karnataka Drug Controlling Authority on a residential property in C.K. Tandya village. That raid triggered a local FIR at Tavarekere police station under Section 318(4) of the Bharatiya Nyaya Sanhita and Section 63 of the Copyright Act. Because these constitute scheduled predicate offences, federal investigators stepped in to untangle the financial paper trail.
The operation was brazen. And dangerous. An operative identified as R. Prashanth allegedly secured a farmhouse near Bidadi to run an unlicensed manufacturing, repackaging, and relabelling hub. Unregulated bulk pharmaceutical compounds—trucked in from manufacturing units across multiple states—were poured into fresh glass vials. The accused then slapped fake labels of global pharmaceutical maker Pfizer onto the containers. They targeted critical hospital-grade treatments: Zavicefta and Emblaveo. Both are sophisticated, high-cost intravenous therapies that clinical teams rely on to beat severe, drug-resistant bacterial infections. Yet inside the bottles sat unauthorized, unverified generic solutions.
Pharmaceutical counterfeiting creates silent clinical crises. When critical-care physicians administer misbranded or substandard intravenous antibiotics for complex systemic infections, patients face delayed recovery, treatment failure, or severe adverse reactions. The racket concealed these vulnerabilities through commercial subterfuge.
According to the investigation, the relabelled vials passed through an intermediary entity named M/s DM Pharmaceuticals before reaching M/s Krupa Healthcare. Krupa Healthcare then sold the lots directly to other pharmaceutical distribution entities and hospitals. To evade safety audits and batch inspections, the syndicate mixed the fake vials directly into genuine product consignments. Unsuspecting hospital procurement desks accepted the shipments, unable to tell real medicine from counterfeit stock at a glance.
A Special Investigation Team led by Bengaluru Joint Commissioner of Police (West) Vamsi Krishna continues to track the domestic supply links alongside drug safety regulators. Meanwhile, federal enforcement officials are tracing the full volume of proceeds generated by the ring, auditing bank books to determine just how far the counterfeit antibiotics travelled into regional clinical networks.